About Us

Chief Executive Officer

  Patrick Mooney is a seasoned leader in ophthalmology, having led several launches and commercialization efforts of ophthalmic pharmaceuticals and medical devices. Most recently, he was Vice President and Head of the Ophthalmology Franchise at Novartis where he was responsible for the overall strategy and growth of U.S. Ophthalmic Pharmaceuticals.  Prior to Novartis, he led sales for Galderma’s Self Medication business unit and was with Alcon for 16 years, holding leadership positions of increasing responsibility in sales, marketing and operations in the United States and Asia. Patrick’s leadership experience in eye care spans the surgical, vision-care and pharmaceutical spectrum, and includes product launches in Retina, Glaucoma, Dry Eye as well as medical devices  Patrick is highly regarded across the industry for his deep insight in the eye care marketplace, his passion for developing and commercializing new products and therapies that improve the lives of patients, and for his focus on developing people, and creating a strong team culture that yields successful business outcomes.

Co-founder, President and 

Executive Chair of the Board

 Dr. Kahook is a practicing ophthalmologist and serial entrepreneur with 15 years of startup and academic experience in research and development. Several of his devices are currently commercialized for clinical use. ClarVista Medical, acquired by Alcon in 2017, developed an advanced modular intraocular lens system co-invented by Dr. Kahook. He is the inventor of the Kahook Dual Blade, which is marketed globally by New World Medical. Dr. Kahook also has extensive experience in intraocular lens material innovation and novel ophthalmic drug delivery methods. His inventions have been the focus of over $150 million in venture backed funding and industry led development and commercialization since 2008 and his devices have been used to treat 100s of thousands of patients globally. 

Co-founder and Chief Technology Officer

 Glenn Sussman is a serial inventor and entrepreneur with 30+ years of experience in the ophthalmic space. Prior to co-founding SpyGlass, he was responsible for the development of a novel IOL for ClarVista Medical which was acquired by Alcon in 2017.  Glenn previously served in an R&D leadership role at Alcon for 18 years. He has supported and led development for several other industry leaders and academic facilities. Glenn has over 60 issued US patents in areas that range from intraocular lenses to surgical devices for ophthalmic surgery. 

Chief Operating Officer

James Dennewill brings over 20 years of medical device industry experience, specializing in the development of products, people and processes required to bring new technologies to market. Prior to SpyGlass, he spent over six years with Cianna Medical (acquired by Merit Medical), where he held various positions of escalating responsibility including VP of Operations and COO. James also spent over 10 years with Med-Logics, Inc., where he managed the development of ophthalmic products, resulting in a range of U.S. and international patents, and served as Management Representative for all regulatory affairs.